A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- 29 Nov 2017 Status changed from suspended to recruiting.
- 23 Jun 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 01 Jun 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2020 as reported by ClinicalTrials.gov